GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors

被引:36
作者
Ahrén B. [1 ]
机构
[1] Department of Clinical Sciences, Division of Medicine, Lund University
关键词
Metformin; Pioglitazone; Liraglutide; Exenatide; Sitagliptin;
D O I
10.1007/s11892-007-0056-9
中图分类号
学科分类号
摘要
Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A1c by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:340 / 347
页数:7
相关论文
共 53 条
[1]  
Drucker D.J., Nauck M.A., The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 368, pp. 1696-1705, (2006)
[2]  
Dunning B.E., Foley J., Ahren B., Alpha-cell function in health and disease: Influence of GLP-1, Diabetologia, 48, pp. 1700-1713, (2005)
[3]  
Nauck M.A., Niedereichholz U., Ettler R., Et al., Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 6, (1997)
[4]  
Gutzwiller J.P., Drewe J., Boke B., Et al., Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2, Am J Physiol, 276, (1999)
[5]  
Perfetti R., Hui H., The role of GLP-1 in the life and death of pancreatic beta cells, Horm Metab Res, 36, pp. 804-810, (2004)
[6]  
Ahren B., Schmitz O., GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes, Horm Metab Res, 36, pp. 867-887, (2004)
[7]  
Meier J.J., Nauck M.A., GIP as a potential therapeutic agent?, Horm Metab Res, 36, pp. 859-866, (2004)
[8]  
Gutniak M., Orskov C., Hoist J.J., Et al., Antidiabetic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus, N Engl J Med, 326, pp. 1316-1322, (1992)
[9]  
Zander M., Madsbad S., Madsen J.L., Holst J.J., Effect of 6-week course of glucagon-like peptide I on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study, Lancet, 359, pp. 824-830, (2002)
[10]  
Mentlein R., Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides, Regul Pept, 85, pp. 9-24, (1999)